Abstract
Objective: To identify and describe the most relevant complications of circulatory support through Oxygenation by venoarterial Extracorporeal Membrane (ECMO-VA) in the terminal treatment of Heart Failure (HF). Bibliographic review: HF is a clinical syndrome characterized by a structural or functional deficit, which compromises ventricular functionality, resulting in an inadequate supply of metabolic tissue needs. Thus, the use of the Extracorporeal Membrane Oxygenation (ECMO) support is indicated in five situations: bridge for recovery, bridge for decision, bridge for long-term devices, bridge for transplant and destination therapy. Therefore, ECMO-VA support is indicated to offer cardiac support with preserved lung function or not. In addition, during ECMO assistance, complications secondary to treatment occur that may be related to the patient's clinical condition or the device. Final considerations: It is well known that this invasive procedure is one of the most viable alternatives due to its final benefits and positive results in the recovery of patients.